LARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for LARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo offers hope for hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink or control advanced head and neck cancer that has grown after initial therapy. About 40 adults whose cancer has spread or returned will receive the combination. The goal is to see how ma…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New program aims to speed up radiation for head and neck cancer patients
Disease control Recruiting nowThis trial tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery. The program provides education, social support, and better coordination among doctors. Researchers will compare it to usual care in 532 adults w…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New coordination system aims to cut cancer treatment delays
Disease control Recruiting nowThis study tests a new care coordination system called PRONTO-HN for head and neck cancer patients. The system uses a risk model to identify patients likely to need radiation after surgery and then coordinates appointments and alerts to reduce delays. Researchers will compare 85 …
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 26, 2026 18:30 UTC
-
Can immune markers predict success of docetaxel chemoradiotherapy?
Knowledge-focused Recruiting nowThis study looks at immune markers in tumor tissue, saliva, stool, and blood from 250 head and neck cancer patients who cannot receive cisplatin chemotherapy. Researchers want to see if these markers can predict how well patients respond to chemoradiotherapy with docetaxel. The g…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC